[PDF] Top 20 Considerations in the development of circulating tumor cell technology for clinical use

... drug development, monitoring the course of disease in cancer patients, and in understanding the biology of cancer pro- ...general clinical acceptance for technologies currently under ...well-annotated ... See full document

... Allogeneic Tumor Cell Vaccines An unresolved question regarding the use of whole tumor cell preparations is the relative immunogenicity of shared versus unique tumor ...unique ... See full document

... and clinical studies have focused on identifying patient parameters that are predictive of symptom- atic VTE (8); these parameters include the site of the cancer, prechemotherapy platelet count, hemoglobin levels, ... See full document

... enormous. Tumor heterogeneity, especially intratumoral heterogeneity, is a significant reason under- lying difficulties in tumor treatment and failure of a number of current therapeutic modalities, even of ... See full document

... the use of fluorescent markers, flow cytometry [30, 31] is one of the most mature technologies for analyzing and sorting subpopulations of ...providing Clinical Laboratory Improvement Amendments ... See full document

... made use of a commercially available CTC detection method, the Parsortix micro fluidic technology, customised to detect both single and clustered GBM CTCs in an antigen-independent manner and at > 98% ... See full document

... biomarker can be helpful for diagnosis, risk assessment, prediction of benefits from a specific treatment, and evaluation of recurrence or progression of cancer. 4-6 Although studies of CTCs in RCC patients are limited, ... See full document

... CTCs are tumor cells in the blood that are disseminated from the site of a primary or metastatic tumor. The detection and characterization of CTCs as a complementary biomarker can be helpful for diagnosis, ... See full document

... The Cell- Search (Veridex) system utilizes ferrofluids loaded with an EpCAM antibody to capture CTCs, staining positive for cytokeratins and negative for CD45 [41], and is currently the only ...approved ... See full document

... anti-target cell antibodies to separate tumor cells directly under the influence of magnetic ...the Cell-Search™ System (CSS: Veridex LLC, NJ, USA), which is the first and only product in the world ... See full document

... resistance development, or prognosis in the metastatic ...the clinical setting of primary disease. In this clinical setting, blood analysis can yield very low numbers of CTCs 129 , with the only way ... See full document

... of circulating tumor cells (CTC) because of their suggested important role in early cancer diagnosis and prognosis, namely, providing easy access by a liquid biopsy from blood to identify metastatic cells ... See full document

... of circulating tumor cell (CTC) clusters than single ...of tumor metastasis and can lead to the development of cancer diagnosis and prognosis, drug screening, detection of gene ... See full document

... separation technology [ 55 ...or tumor-specific antigens expressed by tumor cells or negatively select for CTCs by targeting contaminating blood cell antigens such as CD45 (see Figure 2 C) [ ... See full document

... any tumor cell surface ...cancer cell genome may still be detected by our approach, which facilitates dynamic monitoring of CTCs for treatment response and tumor ... See full document

... epithelial cell adhesion molecule (EpCAM), a protein that protrudes from the outer surface of CTCs, but not healthy blood cells ( Table 1 ...this technology proved suf ficient to provide prog- nostic ... See full document

... ogy, cell physics, materials science, chemistry, nanotech- nology, and ...The cell search system involving surface antigen screening and enrichment possess the ease of automation and high ...its ... See full document

... measuring circulating miRNAs, cell-free or CTC associated, has proven to be feasible, can generate tumor-specific results, and may thus be of clinical relevance if their expression can be ... See full document

... measuring circulating miRNAs, cell-free or CTC associated, has proven to be feasible, can generate tumor-specific results, and may thus be of clinical relevance if their expression can be ... See full document

... primary tumor, which may be followed by radio- and chemotherapy ...grading, tumor location, radiographic findings, and the TNM system ...the tumor size (T), lymph node status (N), and the presence of ... See full document